Quick Read – JNJ earns a BUY at $277.85 (9% upside, 90% confidence), powered by oncology drugs growing as much as 83% and a 66% one-year stock surge. – Pfizer’s P/E of 14 and 6% yield look cheaper than JNJ, but the discount reflects post-COVID erosion; Merck’s acquisition…
arges similarly cloud its earnings picture. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today
Johnson & Johnson (NYSE:JNJ) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook. Our proprietary model sees room to run. Our 24/7 Wall St. price target for JNJ is $277.85, implying 9.45% upside from the current $253.85.
The recommendation is buy with 90% confidence, high by our standards for a mega-cap. 24/7 Wall St. Price Target Summary A Year of Accelerated Growth Is Playing Out JNJ delivered Q1 2026 revenue of $24.06 billion, up 9.9% year over year, with adjusted EPS of $2.70 beating the $2.6773 consensus. Q2 2026 reinforced the trajectory with reported sales of $25.3 billion (up 6.6%) and adjusted EPS of $2.90, prompting another guidance raise.